LRRK2
LRRK2-G2019S and related variants — biology, prevalence and trial enrichment.
State of the art
No update yet for LRRK2. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Genome-wide association and population-tailored polygenic risk for Parkinson’s disease in Taiwan
Among 4,500+ Taiwanese participants, carrying both East Asian LRRK2 risk variants (p.G2385R and p.R1628P) conferred ~4.3× the Parkinson's odds of non-carriers versus ~1.5× for a single variant — the clearest gene-dosage evidence yet for these alleles, with double-variant carriers representing 0.8% of PD cases versus 0.2% of controls. -
PD GENEration: An International Parkinson's Disease Genetic Research Study
PD GENEration's 20,000+ person international cohort, now including Latin American countries and Israel, provides the largest cross-ancestry picture of LRRK2 prevalence in people already diagnosed with Parkinson's. LRRK2 variants were identified in approximately 2.4% of participants in the North American phase; the international data help clarify how rates shift across populations where certain LRRK2 variants are more or less common. -
バイオジェンとデナリ、パーキンソン病治療薬の開発を中止 執筆 - Investing.com - FX | 株式市場 | ファイナンス | 金融ニュース
The LUMA failure sharpens the question of whether LRRK2 inhibition is only relevant for people who actually carry an LRRK2 pathogenic variant. Denali's ongoing BEACON Phase 2a study in LRRK2-variant carriers is now the key remaining test of this hypothesis, with results expected H1 2027 — making genetic status increasingly important for trial eligibility.